Adolescent Obesity Study

29 05 2009

Drs. Timothy Halliday and Sally Kwak, economics professors at the University of Hawaii at Manoa, recently published a paper in Economics and Human Biology titled, “Weight Gain in Adolescents and Their Peers.” The article examines trends in adolescent body mass index (BMI) in a nationally representative dataset.

In their study, Halliday and Kwak document strong correlations in weight gain between adolescents and their friends, even after controlling for confounding factors such as race, sex and age. While these correlations may be indicative of pupils causing their peers to gain weight, the authors provide evidence that a substantial part of the correlations is a consequence of sorting on BMI.

In addition, they discuss many of the econometric issues in estimating such effects while accounting for growth spurts and difficulties in defining adolescent obesity. Halliday and Kwak discuss policy implications of such findings for schoolbased interventions to combat obesity. Their work contributes to a growing body of literature studying the impact of peers on student outcomes.

Click here to view a copy of the abstract.

Source
Timothy Halliday





Weltnichtrauchertag: Abschreckende Fotos für Raucher

29 05 2009

Ekelhafte Lungentumore oder Zahnfleischgeschwüre – die WHO will mit Fotos auf Zigarettenpackungen Raucher abschrecken

Jährlich sterben über fünf Millionen Raucher an ihrer Sucht

Die Weltgesundheitsorganisation WHO fordert anlässlich des Weltnichtrauchertages am 31.Mai, Zigarettenschachteln mit abschreckenden Fotos zu versehen. Weltweite Umfragen würden dokumentieren, dass ekelhafte Bilder von Raucherkrankheiten dazu animieren, den Glimmstängel beiseite zu legen. Denn Fotos würden die Gefahren mehr veranschaulichen als Text-Warnungen, schreibt die WHO.

Mehr als fünf Millionen Raucher sterben weltweit pro Jahr an ihrer Sucht – das sind mehr Todesfälle durch Rauchen als durch HIV/Aids, Malaria und Tuberkulose zusammen, so die WHO.





Obama Interviews Appeals Court Judge Wood For Supreme Court Nomination

29 05 2009

President Obama on Wednesday held a private meeting with Appeals Court Judge Diane Wood to discuss her possible nomination to the Supreme Court, the New York Times reports. The meeting is thought to be Obamas first oneonone interview with a potential candidate to replace retiring Justice David Souter. A White House official said that other possible nominees will be interviewed. According to the Times, White House aides expect an announcement no earlier than next week (Zeleny, New York Times, 5/21).

According to the AP/Google.com, Wood was in Washington, D.C., to attend a Georgetown University Law Center conference on the importance of judicial independence. Wood declined to comment on the meeting with Obama or the Supreme Court vacancy. Solicitor General Elena Kagan, another possible candidate, also attended the conference, where she delivered the keynote address (Sherman, AP/Google.com, 5/20). Kagan in her speech paid tribute to former Supreme Court Justice Sandra Day OConnor, who was being honored at the conference, and discussed the independence of the Office of the Solicitor General. According to the Washington Post, conservative groups already are criticizing Wood and Kagan, as well as potential candidates Appeals Court Judge Sonia Sotomayor and Michigan Gov. Jennifer Granholm (D). The Post reports that Wood “is held in high esteem in liberal legal circles in Chicago for serving as an intellectual counterpart to the circuits star conservative judges.”

The Post reports that Obama has solicited the opinions from senators of both political parties, including every member of the Senate Judiciary Committee. Robert Gibbs, Obamas press secretary, said that Obama is “very active” in the decisionmaking process and that the nomination process is “something that hes quite familiar with” (Barnes/Murray, Washington Post, 5/21).

Reprinted with kind permission from nationalpartnership.org. You can view the entire Daily Womens Health Policy Report, search the archives, or sign up for email delivery here. The Daily Womens Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.

© 2009 The Advisory Board Company. All rights reserved.





What Is Yeast Infection Or Candidiasis? What Is Vaginal Thrush?

29 05 2009

Vaginal thrush (thrush) is a yeast infection caused by a type of fungus of the candida species, usually Candida albicans. It can affect all women, but is more common among women who are pregnant, those who have weakened immune systems, and women aged 30 to 50. Thrush is generally recurring it comes back. The fungus, candida albicans, exists naturally in the vagina. As long as it does not multiply too much a woman will not notice it is there. However, if can sometimes multiply to such an extent that it causes swelling of the vagina and vulva.

The vulva refers to the external genital organs of the female. In laypeoples speech the vagina is used to refer to female genitals in general. However, strictly speaking, the vagina refers to the internal structure, while the vulva refers to the whole exterior. In this article, the two terms are used with their proper meanings.

Candidal balanitis (inflammation of the head of the penis) can develop in the male partners of women with thrush; however, it is very rare. Male genital yeast infection is much less common than female genital yeast infection.

Thrush is not considered to be a sexually transmitted infection.Interesting related articles

Defense mechanism of leading fungal pathogen identified

Genetic Key To Treating Deadly Fungal Infections Discovered By University Of Minnesota Researchers

Women Often Misdiagnose And SelfTreat Yeast Infection

New Strategy To Treat Candida albicans Infection

Top Cause Of Painful Sex Uncovered

Women With Vulvodynia Can Find Relief With Physical TherapyWhat are the symptoms of vaginal thrush? Itching of the vulvaSoreness and irritation in the vulvaVaginal dischargeSuperficial dyspareunia (pain, discomfort during sexual intercourse) Dysuria (discomfort, pain during urination) Women can also experience inflammation of the vagina/vulva (vulvovaginal inflammation). The signs of vulvovaginal inflammation are
The vagina and/or vulva become red (erythema) The skin of the vagina cracksSwelling (if the swelling becomes severe there can be inflammation) Sores in the surrounding area (rare) If a woman has sores in the surrounding areas, this could also be an indication of other fungi, or herpes simplex.

A vaginal discharge is also common. The discharge might be watery, white, or with pus (purulent).What are the causes of thrush? Who is more susceptible to thrush? In most cases, thrush is caused by the Candida albicans fungus. This fungus is generally present in the mouth and vagina.Pregnancy changes in a pregnant womans hormone levels may make her more susceptible to develop thrush.
Diabetes if a womans diabetes is poorly controlled, she is at a significantly higher risk of developing thrush.
Antibiotics when women take antibiotics their chances of developing thrush increase substantially. According to the NHS (National Health Services, UK), approximately 30% of women who take systemic or intravaginal antibiotics develop thrush.
Weakened immune system women with a weakened immune system, such as with HIV/AIDS, recipients of chemotherapy, and lupus are more likely to develop thrush, compared to other women.
Contraceptives some studies indicate that oral contraceptives raise the risk of thrush. However, other studies indicate there is no increased risk.
Oral sex women who have oral sex are at greater risk of developing thrush (the woman being the recipient of oral sex).There is evidence that tight fitting clothing may raise the risk of developing thrush. However, this is not the case with sanitary towels.Diagnosis of thrushA doctor will diagnose thrush by checking for the signs and symptoms. However, if the thrush is recurring, even after treatment, it is advisable to have a vaginal secretion test to make sure it really is a fungus causing the problem, and not another condition, such as bacterial vaginosis, or trichomoniasis.What is the treatment for thrush? A 1 to 3 day course of antifungal medicine will usually be enough to clear up the infection. If the symptoms are severe the treatment will last longer.

Medications can be taken orally (by mouth) or intravaginally. Medications administered intravaginally for thrush are called intravaginal pessaries.

Oral medications can have some sideeffects, including nausea, upset stomach, constipation, diarrhea, vomiting, and/or bloating.

Intravaginal pessaries include clotrimazole, econazole, or miconazole. They are much less likely to cause side effects, however, they can be awkward to use and cause mild irritation when inserted. Some women say they cause stinging initially. They can also damage latex condoms and diaphragms (types of contraceptives).

If the patient is aged 1216 she is generally given an oral antifungal, such as fluconazole, or itraconazole.

If a woman has sores in her vulva there are topical creams that can be applied, such as clotrimazole or econazole.

If the thrush does not clear up after treatment the patient should tell her doctor.

Pregnant and breastfeeding women must take intravaginal pessaries and not oral antifungal medications, as they can be passed on to the baby. Examples of intravaginal pessaries prescribed for pregnant and breastfeeding mothers are clotrimazole, econazole, or miconazole. A full course usually lasts for seven days or more.

Pregnant women must be careful when inserting a pessary with an applicator, as this may injure the cervix. In most cases, application by hand is recommended.

Some medications are available without the need for a doctors prescription. Flucanozole is an OTC (overthecounter) medication in most countries, and is available usually as a single dose tablet.

Women who have developed thrush for the first time are advised to see their doctors, rather than going to the pharmacy to selftreat. It is important that thrush is diagnosed initially. Also, overthecounter medications should not be used longterm without checking with a doctor first this would be discussed during a womans initial doctors visit and/or subsequent ones.Things you can do to ease the symptoms of thrush Avoid using perfumed soaps, vaginal deodorants, shower gels, or douches to wash your vaginal area. Use just water.Avoid using latex condoms.Avoid using spermicidal creams.Avoid using lubricants.Avoid wearing synthetic clothes, and tightfitting clothes. Cotton underwear is best.The following women should go back to see their doctor if symptoms return Pregnant women.
Those with lower abdominal pain (stomach pain) .
Women whose symptoms have changed.
Women who have not seen a doctor for over a year and have had two recurrences in a 12month period.
A woman who has had an STI (sexually transmitted disease) previously (or her partner) .
A woman whose antifungal medications were ineffective.
A woman who has had a bad reaction to antifungal medication.Maintenance therapy for thrushMaintenance therapy is a term used for managing recurring thrush. Studies indicate that oral fluconazole, taken weekly is effective in preventing recurrence. Other studies have also found that oral itraconzole, or intravaginal clotrimazole, taken monthly, are also effective.





New Contraceptive Device Developed By Weill Cornell Researchers Is Designed To Prevent Sexual Transmission Of HIV

29 05 2009

Researchers from Weill Cornell Medical College have published results showing that a new contraceptive device may also effectively block the transmission of the HIV virus. Findings show that the device prevents infection by the HIV virus in laboratory testing. The promising results are published in the most recent issue of the journal AIDS.

The new device is a vaginal ring that releases multiple types of nonhormonal agents and microbicides, which would prevent conception as well as sexually transmitted HIV infection.

Worldwide, there are about 5 million new infections and 3 million deaths per year due to HIV/AIDS. If proven successful in future clinical trials, the new device could empower women to effectively and conveniently protect themselves from unintended pregnancy and sexually transmitted infection. The ring may also someday represent a novel method to prevent STIs for those with aversion to currently available methods, with hormonally derived active agents, or with allergies to latex condoms.

“This device is a new approach to birth control, because it avoids the longterm use of hormonal methods that have been associated with increased risk of certain cancers,” says Dr. Brij Saxena, lead author and the Harold and Percy Uris Professor of Reproductive Biology and professor of endocrinology in the Department of Obstetrics and Gynecology at Weill Cornell Medical College. “At the same time, this is the first device to simultaneously offer the possibility to prevent unintended pregnancy and HIV transmission.”

“No one has ever conquered a viral epidemic with treatment, so prevention is the most effective option. Ideally, an HIV vaccine is the most desirable method, but that is not foreseeable in the near future,” explains Dr. Jeffrey Laurence, coauthor of the study and attending physician at NewYorkPresbyterian Hospital/Weill Cornell Medical Center. “The next best thing would be something that would prevent infection and put the power in the susceptible female partners control. Thats the potential a device such as this can offer.”

The vaginally inserted ring is incorporated with multiple antiviral drugs that prevent HIV infection and are timereleased over a period up to 28 days. The compounds tested were a newly developed antiHIV agent, Boclysinated betulonic acid, TMC120 (dapivirine), PMPA, and 3azido3deoxythymidine (AZT or zidovudine), which, when combined, were found to block infection in human cells exposed to the virus in a laboratory setting.

“The combination of these antiviral drugs has proven to be potent agents that may block infection by the HIV virus,” says Dr. Saxena.

The ring is also incorporated with compounds that prevent conception by arresting sperm motility, raising vaginal mucous viscosity, and sustaining the acidity of the vagina in which sperm do not survive. Traditionally, similar devices have used hormonal compounds that have been linked to increased risk of breast and cervical cancers, or spermicidal compounds that kill sperm, but may lead to irritation and inflammation. Past findings published in the journal Contraception found the device to be highly effective in animal models and in laboratory testing.

“The compounds in the device are natural materials that are already approved by the U.S. Food and Drug Administration for use in humans,” explains Dr. Saxena.

The study was supported by grants by the National Institutes of Health, International Partnership for Microbicides and BioRing LLC.

Collaborators on this study include Dr. Young A. Han and Dr. Mukul Singh from Weill Cornell Medical College, Dr. Dingyi Fu and Dr. Premila Rathnam formerly of Weill Cornell, and Sidney Lerner from BioRings LLC.

Drs. Saxena and Singh are vice presidents at BioRings LLC and along with Mr. Lerner, president of BioRings LLC, are coinventors and owners of U.S. and foreign patents on the technology used in this research. Cornell Research Foundation (CRF) owns pending patent applications related to the research.





Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting

29 05 2009

Ascenta Therapeutics announced that eleven presentations or publications on preclinical and clinical studies of AT101, an oral, panBcl2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29June 2, in Orlando, Florida.

Prostate Cancer

MacVicar G, et al. An openlabel, multicenter, phase I/II study of AT101 in combination with docetaxel (D) and prednisone (P) in men with castrate resistant prostate cancer (CRPC). Abstract #5062; Poster Board #17; Poster Discussion, May 31, 800 a.m.1200 p.m.

Poiesz B, et al. Preliminary report of an openlabel, multicenter, phase I/II study of AT101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. Abstract #5145; Poster Board #J13; GU General Poster Session, May 31, 200 p.m.600 p.m.

Glioma

Fiveash J, et al. NABT0702 A phase II study of AT101 in recurrent glioblastoma multiforme (GBM). Abstract #2010; Poster Board #2; Poster Discussion, May 30, 800 a.m.1200 p.m.

Lung Cancer

Heist R, et al. A phase I/II study of AT101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum containing first line chemotherapy. Abstract #8106; Poster Board #R14; Lung Cancer Metastatic, May 30, 200 p.m.600 p.m.

Ready N, et al. AT101 or placebo (P) with docetaxel (D) in second line NSCLC with gene signature biomarker development. Abstract #3577; Poster Board #J19; Developmental Therapeutics, May 30, 800 a.m.1200 p.m.

Min P, et al. Small molecule panbcl2 inhibitor AT101 induces apoptosis in NSCLC by upregulating noxa and enhances antitumor activity of docetaxel or targeted kinase inhibitors. Abstract #e14591; Publication only.

NonHodgkins Lymphoma

Kingsley E, et al. An openlabel, multicenter, phase II study of AT101 in combination with rituximab (R) in patients with untreated, grade III, follicular NonHodgkins Lymphoma (FL). Abstract #8582; Poster Board #S11; Lymphoma and Plasma Cell Disorders, May 30, 800 a.m.1200 p.m.

Advanced Cancers

Leal TB, et al. A phase I study of AT101 in combination with cisplatin (P) and etoposide (E) in patients with advanced solid tumors and extensivestage small cell lung cancer (ESSCLC). Abstract #e13502; Publication only.

Saleh M, et al. Extended phase I trial of the oral panBcl2 inhibitor AT101 by multiple dosing schedules in patients with advanced cancers. Abstract #e14537; Publication only.

Mechanism of Action/Pharmacokinetics

Wang S, et al. AT101 induces transcriptional upregulation of Noxa and Puma and overcomes Mcl1mediated cancer cell resistance to apoptosis. Abstract # e14611; Publication only.

Pitot H, et al. Analysis of a phase I pharmacokinetic (PK)/food effect study of AT101 in patients with advanced solid tumors. Abstract #2557; Poster Board #B18; Developmental Therapeutics, May 30, 800 a.m.1200 p.m.

About AT101

AT101 is an orallyactive, panBcl2 inhibitor (including Bcl2, BclxL, Bclw, and Mcl1 inhibition) that has been shown to induce apoptosis directly by operating as a BH3 mimetic and indirectly as an independent upregulator of Noxa and Puma. By blocking the binding of Bcl2 family members with proapoptotic proteins and upregulating specific proapoptotic factors, AT101 lowers the threshold for cancer cells to undergo apoptosis in various tumor types. In Phase I and Phase II trials, AT101 has demonstrated singleagent cytoreductive activity in several cancers, including chronic lymphocytic leukemia (CLL), nonHodgkins lymphoma (NHL), and prostate cancer. Phase II combination trials are ongoing in several cancers, including hormonerefractory prostate cancer and nonsmall cell lung cancer (with Taxotere(R)), Bcell malignancies (with Rituxan(R)), small cell lung cancer (with Hycamtin(R)), glioma (with Temodar(R), +/ chemoradiotherapy [XRT]) and esophageal cancer (with docetaxel, 5fluorouracil and XRT).

About Ascenta Therapeutics

Ascenta Therapeutics, Inc. is a privatelyheld, clinicalstage biopharmaceutical company that discovers and develops new medicines for the treatment of cancer. The company is headquartered in Malvern, Pennsylvania, and has a preclinical research facility in Shanghai, China. Its technology, licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan, is focused on discovering molecules that restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascentas lead agent, AT101, is an orallyactive small molecule pan Bcl2 inhibitor (Bcl2, BclxL, and Mcl1) currently in Phase 2 clinical trials in castrate resistant prostate cancer. The Companys preclinical pipeline includes the oral multiIAP antagonist AT406, and an HDM2p53 inhibitor program.





Opinion Pieces Respond To Obamas Call For Empathy In Supreme Court Justice

29 05 2009

Two newspapers recently published opinion pieces responding to President Obamas comments on the need for “empathy” in candidates to replace retiring Supreme Court Justice David Souter. Summaries appear below.

~ Ellen Goodman, Boston Globe When discussing Souters replacement, Obama said he will seek a nominee “who understands that justice isnt about some abstract theory. … It is also about how our laws affect the daily realities of peoples lives,” Globe columnist Goodman writes in an opinion piece. According to Goodman, Obamas emphasis on the need for judicial “empathy” has sparked outrage among a “phalanx of horrified conservatives” who claim that “empathy is just a code word for the sentimental liberal bias in favor of underdogs over the Constitution.” However, she continues, “let us remember that empathy is not sympathy. It doesnt require that we take sides. Nor is it an emotional shortcut that upends all legal reasoning to declare a winner.” According to Goodman, empathy “is rather the ability to imaginatively enter into the experience of others.” She writes that the “capacity to recognize another persons reality is not just liberal,” adding that empathy “doesnt trump reason, it informs reason.” Goodman writes, “The truth is that we want judges who get it,” adding that the “myth of justice as a matter of pure objective reasoning that could be meted out by a computer is just that, a myth” (Goodman, Boston Globe, 5/22).

~ Mike Rosen, Denver Post Although Obamas emphasis on empathy might seem “[c]ompassionate and seductive” to some, his stance “represents a radical and dangerous departure from traditional American jurisprudence,” radio host Rosen writes in a Post opinion piece. Rosen writes, “When empathetic judges rule on their feelings, they are exceeding their authority,” adding that the “role of the judicial branch of our government is to rule on the Constitution as written and the law as passed by Congress and signed by the president.” According to Rosen, the courts “are a coequal branch of government, not a superior branch,” and judges should not “rule on what they think the law ought to be” because that would be “government by a presumptuous, unelected judiciary.” Rosen continues that “judges are referees, not rule makers” because they are “not there to empathize with the fans or the players. They represent the rule book, and they arent authorized to … make it fairer.” According to Rosen, the “dispute between conservatives and liberals on judicial activism is philosophical and irreconcilable.” He concludes that Senate confirmation hearings for Obamas nominee “should make for an interesting debate on these principles” (Rosen, Denver Post, 5/22).

Reprinted with kind permission from nationalpartnership.org. You can view the entire Daily Womens Health Policy Report, search the archives, or sign up for email delivery here. The Daily Womens Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.

© 2009 The Advisory Board Company. All rights reserved.





South African Health Minister To Launch PMTCT Plan

29 05 2009

South African Health Minister Aaron Motsoaledi within the next two weeks is expected to launch a plan to address mothertochild HIV transmission in an effort to reduce infant mortality in the country, The Times reports. The MTCT plan is part of a new health program adopted by President Jacob Zumas administration, according to The Times.

“This is one of the most urgent things I want to (deal with) as the new minister,” Motsoaledi said. According to Motsoaledi, a child dies every eight minutes in South Africa, and about 40% of child deaths are related to HIV/AIDS. The plan was developed by the Development Bank of Southern Africa at a July meeting of government and health sector stakeholders. Participants at the meeting also examined maternal deaths and the decrease in life expectancy among young adults because of HIV/AIDS. According to Motsoaledi, these and other issues have been identified as priorities for the Zuma administration if South Africa is to meet targets in the United Nations Millennium Development Goals. They also have been consolidated into a 10point plan to help the Department of Health focus on urgent issues through 2015.

“Health and education are the biggest challenges for (the government) and we ought to be doing something drastic,” Motsoaledi said, adding, “These are very serious issues in society.” The health departments plan also calls for the revival of the National AIDS Council and says that the government should improve regulation of the private health sector. It also calls for the establishment of a national tuberculosis reference laboratory, a focus on infection rates among women ages 17 to 21 and the improvement of HIV prevention among commercial sex workers (Molele, The Times, 5/25).

Reprinted with kind permission from kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.





Offsprings Behavior Influenced By Trauma Experienced By The Mother Even Before Pregnancy

16 05 2009

A new study in rats at the University of Haifa reveals that tauma experienced by a mother even before pregnancy will influence her offsprings behavior.

*”The findings show that trauma from a mothers past, which does not directly impact her pregnancy, will affect her offsprings emotional and social behavior. We should consider whether such effects occur in humans too,” stated Prof. Micah Leshem who carried out the study.*

A mother who experienced trauma prior to becoming pregnant affects the emotional and social behavior of her offspring. This was discovered for the first time in a new study that was carried out at the University of Haifa and published in the journal Developmental Psychology in a Special Section on “The Interplay of Biology and the Environment Broadly Defined.”

The effects of trauma that a mother experienced in the course of pregnancy are known from earlier research, but until now the influence of adversity before conception has not been examined. The present research, carried out by Prof. Micah Leshem and Alice ShacharDadon of the University of Haifa and Prof. Jay Schulkin of the Georgetown University School of Medicine, is the first to examine these influences.

The researchers chose to investigate rats, as social mammals with cerebral activity that is similar in many ways to that of humans. The present study examined three groups of rats one group was put through a series of stressinducing activities two weeks before mating, allowing the female time to recover before becoming pregnant; the second group was similarly treated over the course of a week immediately prior to mating; and the third, control group, were not given any form of stress. When the rats offspring reached maturity (at 60 days), the researchers examined their emotional behavior anxiety and depression and social behavior.

The main finding revealed that trauma experienced by the females prior to conception had varied effects on the offspring. According to Prof. Leshem, these effects varied between groups and between male and female offspring; but their behavior was without doubt different from that of the rats from the control group.

All the offspring of stressed mothers showed reduced social contact compared with that of the control mothers offspring these rats spent less time with one another and interacted less. In other tests, there were important sex differences. The female rats displayed more symptoms of anxiety, while the males exhibited less anxiety. Finally, those rats whose mothers became pregnant immediately after being stressed were hyperactive, indicating that how long before pregnancy adversity is experienced, is also important. “Everyone knows that smoking harms the fetus and therefore a mother must not smoke during pregnancy. The findings of the present study show that adversity from a mothers past, even well before her pregnancy, does affect her offspring, even when they are adult. We should be prepared for analogous effects in humans for example, in children born to mothers who may have been exposed to war well before becoming pregnant,” Prof. Leshem concluded.

Source
Rachel Feldman





Date-Pannen vermeiden: Samstag bester Tag fürs erste Rendezvous

15 05 2009

Am Wochenende haben die meisten Zeit und Lust, außerdem ist Samstag der Tag mit den meisten Veranstaltungen

Wenn’s was werden soll: Samstag ist der beste Tag für das erste Rendezvous

Samstag ist der beste Tag für die erste Verabredung mit einer neuen Bekanntschaft. Das meint der Diplom-Psychologe und Flirttrainer Stephan Landsiedel aus Wiesentheid. "Natürlich darf auch an anderen Tagen geflirtet werden. Aber Samstag ist nun mal für die meisten der Tag mit der meisten Zeit, der meisten Lust und den meisten Veranstaltungen", sagt der Fachmann in der am 18. Mai erscheinenden Juni-Ausgabe von "Men’s Health". Samstags sind die Lokale und die Kinos deswegen gut besucht. Darum sollte man unbedingt rechtzeitig vorher Plätze reservieren.

Wer das vergisst und dann mit seiner neuen Flamme vor der Tür steht, braucht schon eine gute Strategie, um da wieder rauszukommen. Bei solchen und anderen Peinlichkeiten ist es nach einer Online-Umfrage von "Men’s Health" am besten, einfach mal drauf los zu lachen. Frauen lieben es schließlich, wenn Männer über sich selbst lachen können, meinen 64 Prozent der insgesamt 1456 Umfrage-Teilnehmer, wobei Mehrfachnennungen möglich waren. Sich entschuldigen und einfach frisch weiterplaudern, steht mit 60 Prozent an zweiter Stelle der Tipps bei Dating-Pannen. 22 Prozent halten es für sinnvoll, nach dem Tritt in ein Fettnäpfchen erstmal abzuwarten, ob es überhaupt aufgefallen ist. 5 Prozent raten sogar dazu, den Flirt-Fauxpas erneut zu begehen, so dass es nach Absicht aussieht.

An letzter Stelle in der Rangfolge der Tipps gegen Pannen beim Rendezvous steht mit 4 Prozent die devote Nummer: Man macht der Dame seines Herzens ein Kompliment, bestellt einen Drink – und entschuldigt sich mehrfach. Das kann allerdings schon das nächste Fettnäpfchen sein.